Find a trial

Our clinical trials database will help you look for a clinical trial that might be suitable for you. We hope this helps you to make informed decisions and choices about your lymphoma treatment and care. 

Questions about Lymphoma TrialsLink and how to use it? Read more about Lymphoma TrialsLink here or if you have a general question about clinical trials in the UK or Lymphoma TrialsLink, please contact us at trialslink@lymphoma-action.org.uk.

Note: We are not able to refer people to specific trials. If you’re interested in taking part in a trial you have found on Lymphoma TrialsLink, we recommend that you print the trial summary and discuss it with your consultant. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.

Trial name Sort descending Closing date

ALLCAR19: A phase 1 trial of CAR T-cell therapy in adults with relapsed or refractory DLBCL, CLL, SLL, FL or MCL

ALLELE: A phase 3 trial of a targeted treatment called tabelecleucel in people with post-transplant lymphoproliferative disorder

Ascelus-H: A trial investigating the use of digital follow up for monitoring long term blood conditions

ASTX660-03: A trial testing the addition of tolinapant to treatment regimens in relapsed or refractory peripheral T-cell lymphoma

Athena 1: A phase 1 study of REGN5837 in people with relapsed or refractory B-cell non-Hodgkin lymphomas

AUTO4 in T-cell lymphoma: a phase 1/2 trial testing AUTO4 CAR-T cells as treatment for people with T-cell lymphoma that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

AZD7789: A phase 1/2 trial of AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma

BASILICA-A: A study into why anaplastic large cell lymphoma sometimes occurs after breast implants

BGB-11417 MCL: A trial testing the treatment BGB-11417 in patients with relapsed or refractory mantle cell lymphoma

BGB-11417: A phase 1 trial of BGB-11417 in people with B cell malignancies

BO43243: A phase 1 trial of mosunetuzumab in relapsed or refractory chronic lymphocytic leukaemia (CLL)

BOOST: studying samples from stem cell transplant donors and recipients to improve transplant success rates and reduce side effects

BP41072: A trial testing RO7227166 in people with relapsed or refractory B-Cell Non-Hodgkin lymphoma

BP43131: A phase 1 study to test the safety and efficacy of RO7443904 in combination with glofitamab in people with relapsed or refractory B-cell non-Hodgkin lymphoma

BRUIN CLL-322: A randomised, phase 3 study of pirtobrutinib plus venetoclax and rituximab compared to venetoclax plus rituximab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)

BRUIN-CLL-314: A phase 3 trial of pirtobrutinib compared to ibrutinib in adults with chronic lymphocytic leukaemia

BRUIN-MCL-321: A phase 3 trial of a targeted treatment called pirtobrutinib in people with relapsed or refractory mantle cell lymphoma

BTCT4465A: A trial testing mosunetuzumab in combination with polatuzumab in people with B-cell non-Hodgkin lymphoma

BYON4228: A phase 1 trial of BYON4228 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

CAN3001: A long term study of ibrutinib

CC-99282: A phase 1 trial of CC-99282 alone and in combination with anti-lymphoma agents in people with relapsed or refractory non-Hodgkin lymphoma

CCS1477-02: a phase 1/2a study of CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma

CLOVER-1 and CLOVER-WaM: A phase 2 trial looking at the medication iopofosine I 131 (CLR 131) in people with B-cell lymphomas and an expansion in Waldenstrom Macroglobulinaemia (WM)

CO43805: A Phase 1b trial of mosunetuzumab or glofitamab in people with B-cell Non-Hodgkin Lymphoma

CPI-0209: A study of CPI-0209 in relapsed or refractory diffuse large B-cell and peripheral T-cell lymphomas

Determine trial treatment arm 1: A phase 2/3 trial of alectinib in people with ALK positive lymphomas

DIRECT: A study looking at genetic changes in diffuse large B-cell lymphoma and other types of high-grade B-cell lymphoma

DOLPHIN-VIVO: an observational study looking at diagnosing lymphoma with a less invasive method

DTP3: A phase 1/2 trial of DTP3 in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

EBV: A phase 2 trial of tabelecleucel in people with Epstein-Barr virus associated diseases

ELM-2: a phase 2 trial assessing the safety of odronextamab in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

EPCORE CLL-1: A trial testing epcoritamab in people with relapsed or refractory chronic lymphocytic leukaemia and Richter’s syndrome

EPCORE™ NHL-2: A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma

EPCORE™NHL-1: a phase 1/2 trial of GEN3013 in people with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment

FLAIR: a randomised phase 3 trial comparing treatments containing ibrutinib with standard first treatment for chronic lymphocytic leukaemia (CLL)

Kite: A trial testing KITE-363 and KITE-753 in people with relapsed and refractory B-cell lymphoma

KRT-232: A phase 1b/2 trial of KRT-232 in combination with acalabrutinib in DLBCL or CLL

KT-413: A trial testing KT-413 in people with relapsed or refractory B-cell Non-Hodgkin lymphoma

LOTIS-5: A phase 3 trial of loncastuximab tesirine and rituximab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

MAST: A trial investigating the link between gut health and stem cell transplant outcomes in patients with chronic lymphocytic leukaemia

MK-2140-003: A trial testing zilovertamab vedotin (MK-2140) in people with relapsed or refractory diffuse large B-cell lymphoma

MK-2140-006: A trial testing zilovertamab vedotin in people with selected B-cell lymphoma

MK-4280A-008: A phase 3 trial of favezelimab/pembrolizumab compared to chemotherapy in relapsed or refractory classical Hodgkin lymphoma

MK1026-003: A phase 2 trial of the medication MK-1026 in blood cancers

MOGAT: A phase 2 trial of mogamulizumab in cutaneous T-cell lymphoma

MoTD: A phase 2 trial comparing interventions for the prevention of graft versus host disease after unrelated donor stem cell transplantation.

NAVAL-1: a phase 2 trial of nanatinostat with valganciclovir in Epstein-Barr Virus-Positive relapsed and refractory lymphomas

NuTide:701: a phase 1 trial to find the best dose and test the safety of a new drug called NUC-7738 in people with advanced solid tumours or lymphoma

NVG-111: a phase 1/2 trial of NVG-111 in relapsed or refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma and mantle cell lymphoma

NX-1607: A phase 1 study of NX-1607 in adults with advanced solid tumours

NX-5948-301: A phase 1 study of a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma

OASIS II: A phase 2 trial of potential treatment regimens in people with mantle cell lymphoma

OptiMATe: A phase 3 trial to optimise the MATRix chemotherapy regimen in primary central nervous system lymphoma

OxPLoreD: a study to find out more about pre-cancerous blood conditions

P+R-ICE: A phase 2 trial of pembrolizumab with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

PETReA: a trial testing whether PET scans can help make treatment decisions for people with follicular lymphoma

Pola-R-ICE: A phase 3 trial of combining standard R-ICE chemotherapy with polatuzumab in people with diffuse large B cell lymphoma (DLBCL)

PRiZM+: A phase 1 trial of zanubrutinib in people with relapsed or refractory primary central nervous system lymphoma

PRO-CAR-T: A study to design and test a tool to gather information from patients after CAR-T therapy

PROACT: A phase 3 trial testing whether a drug called enalapril can prevent heart damage linked to chemotherapy in people with lymphoma or breast cancer

PROCLIPI: a study aiming to identify factors important in predicting the outcome of cutaneous (skin) lymphomas, mycosis fungoides and Sezary syndrome

PROSPER: An observational study of Poteligeo in mycosis fungoides or Sezary syndrome

RADAR: A phase 3 trial of an antibody treatment called brentuximab vedotin in people with early stage Hodgkin lymphoma

RAINBOW: a randomised, phase 2/3 trial comparing ibrutinib plus rituximab with standard treatment in people with Waldenström’s macroglobulinaemia

REFRACT: A phase 2 trial comparing new treatments to standard treatment in relapsed or refractory follicular lymphoma

REMIT: A trial looking at radiotherapy as a priming treatment before CAR-T therapy in DLBCL

REMoDL-A: A phase 2 trial of a targeted drug called acalabrutinib added to standard treatment for people with diffuse large B-cell lymphoma

SGN35-032: A phase 2 trial of brentuximab vedotin plus chemotherapy in people with peripheral T-cell lymphoma

STATIC: A study comparing intermittent and continuous treatment with ibrutinib in CLL/SLL

STELLAR: a phase 2 trial of acalabrutinib in people with Richter syndrome

STP938: A phase 1/2 study of STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas

SYMPHONY-1: a phase 1b/3 double-blind, randomised study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Zuma-22: A trial testing axicabtagene ciloleucel in people with relapsed or refractory follicular lymphoma